MapLight Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MPLT research report →
Range $13 – $46
Price Chart
About the company
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis.
- CEO
- Christopher A. Kroeger
- IPO
- 2025
- Employees
- 133
- HQ
- Redwood City, CA, US
Get TickerSpark's AI analysis on MPLT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $253.15M
- P/E
- -1.09
- PEG
- 0.02
- P/S
- 0.00
- P/B
- 0.71
- EV/EBITDA
- 0.81
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -61.01%
- ROIC
- -61.68%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-578,000+17.5%
- Op Income
- $-169,083,000
- Net Income
- $-161,152,000-107.7%
- EPS
- $-3.66-95.7%
- OCF Growth
- -75.3%
- FCF Growth
- -74.2%
- 52W High
- $40.43
- 52W Low
- $5.92
- 50D MA
- $8.63
- 200D MA
- $19.70
- Beta
- 3.01
- RSI (14)
- 30
- Avg Volume
- 458.71K
No earnings-call transcripts are available for MPLT yet.
- Free Float
- 18.7%
- Shares Outstanding
- 42.62M
- Float Shares
- 7.97M
of shares held by institutions
110 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Novo Holdings A/S | 3.69M | 0 |
| Fcpm Iii Services B.V. | 3.23M | 0 |
| T. Rowe Price Investment Management, Inc. | 2.78M | ▼ 20.21K |
| Nan Fung Group Holdings Ltd | 2.30M | ▲ 1.33M |
| Goldman Sachs Group Inc | 1.95M | ▼ 46.56K |
| Blackrock, Inc. | 1.71M | ▲ 687.60K |
| Fmr LLC | 1.54M | ▲ 718.38K |
| Price T Rowe Associates Inc | 1.42M | ▲ 1.31M |
| 5am Venture Management, LLC | 950.01K | 0 |
| Sanofi | 912.04K | 0 |
| Vanguard Group Inc | 869.67K | ▲ 869.67K |
| Paradigm Biocapital Advisors LP | 685.85K | ▲ 685.85K |
Held by 126 ETFs
Biggest fund positions in MPLT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 15, 26 | Kreitzer Anatol | sell | 12,248 |
| Oct 15, 26 | GILLIS JONATHAN | sell | 10,167 |
| Oct 15, 26 | Lillie James Woodruff | sell | 11,513 |
| Oct 15, 26 | Hanson Kristopher | sell | 9,020 |
| Oct 15, 26 | Foff Erin Pennock | sell | 15,355 |
| Oct 15, 26 | Kroeger Christopher A. | sell | 73,691 |
| Sep 16, 26 | Hanson Kristopher | sell | 16,509 |
| Aug 17, 26 | Kreitzer Anatol | other | 6,020 |
| Aug 17, 26 | Kreitzer Anatol | other | 24,455 |
| Aug 17, 26 | GILLIS JONATHAN | other | 2,222 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MPLT coverage
Recent articles, reports, and earnings notes.
No research on MPLT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MPLT report →MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Nov 16
MapLight Therapeutics to Participate in Upcoming Investor Conference
globenewswire.com · Nov 9
Maplight Therapeutics (NASDAQ:MPLT) Insider Sells $93,025.04 in Stock
defenseworld.net · Oct 19
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Insider Sells $96,024.32 in Stock
defenseworld.net · Oct 19
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Insider Sells $124,068.40 in Stock
defenseworld.net · Oct 19
Maplight Therapeutics (NASDAQ:MPLT) CFO Sells $82,149.36 in Stock
defenseworld.net · Oct 19
Down 29.2% in 4 Weeks, Here's Why You Should You Buy the Dip in MapLight Therapeutics, Inc. (MPLT)
zacks.com · Oct 16
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Stock Has Consensus Price Target of $29.50
defenseworld.net · Oct 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.